Official EU label nameGlossary entry 23945
QUININE
This record confirms an official common ingredient name for EU cosmetic product labelling. It does not by itself confirm that the substance is permitted, unrestricted or safe.
Global evidence snapshot
The resolved identity has matching regulatory evidence in 8 of 13 indexed market datasets: 7 country records and 1 EU Annex records. Every result and evidence gap is listed below.
Markets checked
13
Markets with evidence
8
Evidence gaps
5
Resolved identifiers
2
A missing local match is not permission, approval or proof of safety. It means no strong identity match was resolved in that indexed dataset.
Resolved substance identity
CAS:130-95-0
EC:205-003-2
Ingredient index records:
QUININE
Ph. Eur. name: chininum
Cosmetic functions: DENATURANT, FRAGRANCE, HAIR CONDITIONING
Cinchonan-9-ol, 6'-methoxy-, (8.alpha., 9R)-
Inventory restriction note: III/21
9 matched or reported names
QUININEquininechininumCinchonan-9-ol, 6'-methoxy-, (8.alpha.,9R)- its saltsQuinineQuinine (cinchonan-9-ol, 6'-methoxy-, (8alpha, 9R)-) and its saltsCinchonan-9-ol, 6’-methoxy- (8.alpha, 9R)-and its salts’ Quinine and its salts CAS No 130-95-0퀴닌 및 그 염류Cinchonan-9-ol, 6'- methoxy- (8.alpha., 9R)- and its salts Quinine (CAS No. 130-95-0)
Regulatory evidence in all 13 markets
Open each matched record for its scope, concentration, conditions, warnings and official source version.
Swipe or scroll horizontally to see dataset coverage and next actions.
| Market | Result | Records | Dataset | Meaning / next action |
|---|---|---|---|---|
| European Union EU | Restricted | 1Open record 1 | Complete annex dataset Regulation (EC) 1223/2009 consolidated to 1 May 2026 | Review every linked record and exact conditions. |
| Great Britain GB | Restricted | 1Open record 1 | Complete consolidated annex dataset GB retained Regulation 1223/2009 schedules, effective 15 August 2026 | Review every linked record and exact conditions. |
| Canada CA | No local match | 0 | Complete Hotlist snapshot Health Canada Cosmetic Ingredient Hotlist, 13 August 2025 | The Hotlist is an administrative compliance tool, not an exhaustive safety approval list. |
| New Zealand NZ | Restricted | 1Open record 1 | Complete schedules dataset Cosmetic Products Group Standard schedules effective 1 January 2026 | Review every linked record and exact conditions. |
| ASEAN ASEAN | Restricted | 1Open record 1 | Complete regional annex dataset ASEAN Cosmetic Directive annexes 2026-1, 22 June 2026 | Review every linked record and exact conditions. |
| China CN | No local match | 0 | Complete prohibited catalogues plus official-source workflow NMPA 2021 banned catalogues plus dynamic IECIC List I/List II system current since 2025 | IECIC listing is not blanket approval; absence may require the new cosmetic ingredient route, and restrictions are checked separately. |
| Japan JP | No local match | 0 | Complete Standards appendices dataset MHLW Standards for Cosmetics official English source and Japanese amendments checked for the imported snapshot | The Japanese text and subsequent notices are canonical; no local match is not a product-compliance conclusion. |
| South Korea KR | Restricted | 1Open record 1 | Complete current appendix dataset MFDS Notice 2026-19, effective 18 March 2026 | Review every linked record and exact conditions. |
| United States US | No local match | 0 | Complete enumerated federal ingredient rules eCFR Title 21 issue date 27 August 2026 | FDA has no general approved-cosmetic-ingredient catalogue; absence from these sections is not approval or proof of safety. |
| Australia AU | Restricted | 1Open record 1 | Complete cosmetic-relevant Poisons Standard subset plus official workflow Therapeutic Goods (Poisons Standard—June 2026) Instrument 2026 | Review every linked record and exact conditions. |
| Brazil BR | No local match | 0 | Complete prohibited dataset plus current restricted-list workflow ANVISA RDC 1.029/2026 and RDC 1.030/2026, published 15 June 2026 | RDC 1.030/2026 amends rather than replaces the prohibited baseline, and the second restricted-list revision was still under consultation in July 2026. |
| India IN | Restricted | 1Open record 1 | Complete current Part 2 dataset plus official workflow for Parts 1, 3 and 4 Cosmetics Rules 2020 plus current BIS IS 4707 parts (1:2020, 2:2025, 3:2025, 4:2022) | Review every linked record and exact conditions. |
| Saudi Arabia SA | Restricted | 1Open record 1 | Complete official list index SFDA live prohibited/restricted lists, snapshot 30 August 2026 | Review every linked record and exact conditions. |
No market rows match this filter.
Matching market records and conditions
Great Britain
GB retained Regulation 1223/2009 schedules, effective 15 August 2026New Zealand
Cosmetic Products Group Standard schedules effective 1 January 2026ASEAN
ASEAN Cosmetic Directive annexes 2026-1, 22 June 2026South Korea
MFDS Notice 2026-19, effective 18 March 2026Australia
Therapeutic Goods (Poisons Standard—June 2026) Instrument 2026India
Cosmetics Rules 2020 plus current BIS IS 4707 parts (1:2020, 2:2025, 3:2025, 4:2022)Saudi Arabia
SFDA live prohibited/restricted lists, snapshot 30 August 2026Exact Annex II–VI evidence
Annex IIIentry 21
Open full regulatory recordQUININE
Product scope: (a) Hair rinse-off products (b) Hair leave-on products
Maximum concentration: (a) 0.5% (as quinine base) (b) 0.2% (as quinine base)
Chemical identity and properties
CAS 130-95-0PubChem CID 3034034
Quinine
Quinine is a cinchona alkaloid that is cinchonidine in which the hydrogen at the 6-position of the quinoline ring is substituted by methoxy. It has a role as a non-narcotic analgesic, an antimalarial and a muscle relaxant. It is a conjugate base of a quinine(1+). It derives from a hydride of an (8S)-cinchonan. — ChEBI
- IUPAC name
- (R)-[(2S,4S,5R)-5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl]-(6-methoxyquinolin-4-yl)methanol
- Molecular formula
- C20H24N2O2
- Molecular weight
- 324.4 g/mol
- Exact mass
- 324.183778013 Da
- XLogP3
- 2.9
- Topological polar surface area
- 45.6 Ų
- Hydrogen-bond donors
- 1
- Hydrogen-bond acceptors
- 4
- Covalent units
- 1
- Defined stereocentres
- 4
Also known as
ChinineChinin(-)-Quinine(8S,9R)-Quinine6'-Methoxycinchonidine(R)-(-)-quinine6-Methoxycinchoninechininum
16 more reported names
quininaRezquinChininum purum(8S,9R)-6'-Methoxycinchonan-9-ol(R)-(-)-Quinine, 6-methoxycinchonidineA7V27PHC7ACHEBI:15854(8-alpha,9R)-6'-Methoxycinchonan-9-olNSC-192949(R)-(6-methoxyquinolin-4-yl)((2S,4S,8R)-8-vinylquinuclidin-2-yl)methanol2-Quinuclidinemethanol, alpha-(6-methoxy-4-quinolyl)-5-vinyl-(R)-[(1S,2S,4S,5R)-5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl](6-methoxyquinolin-4-yl)methanolQuinsonQuinsul(R)-((1S,2S,4S,5R)-5-ethenyl-1-azabicyclo(2.2.2)octan-2-yl)(6-methoxyquinolin-4-yl)methanol(R)-((2S,4S,5R)-5-ethenyl-1-azabicyclo(2.2.2)octan-2-yl)-(6-methoxyquinolin-4-yl)methanol
External database identifiers
Evidence from additional scientific databases
NIH PubChem PUG-View
Exact identifier match3034034
Attributed physical-property, hazard, environmental and use annotations.
- Color/Form: Triboluminescent, orthorhombic needles from absolute alcohol Source: Hazardous Substances Data Bank (HSDB)
- Color/Form: Bulky, white, amorphous powder or crystalline alkaloid Source: Hazardous Substances Data Bank (HSDB)
- Color/Form: CRYSTALS TURN BROWN ON EXPOSURE TO AIR Source: Hazardous Substances Data Bank (HSDB)
- Basic pKa: 8.56 Source: ChEMBL
- Basic pKa: 8.55 Source: ChEMBL
- Dissociation Constants: pK1 (18 °C) = 5.07; pK2 = 9.7 Source: Hazardous Substances Data Bank (HSDB)
- LogP: 3.44 Source: DrugBank
- LogP: log Kow = 3.44 Source: Hazardous Substances Data Bank (HSDB)
- LogP: 2.6 Source: Human Metabolome Database (HMDB)
- Melting Point: 57 °C Source: DrugBank
- Melting Point: 177 °C (some decomposition) Source: Hazardous Substances Data Bank (HSDB)
- Melting Point: Microcrystalline powder; mp: 57 °C; efflorescent; loses one water molecule in air, two water molecules over sulfuric acid; anhydrous at 125 °C /Quinine trihydrate/ Source: Hazardous Substances Data Bank (HSDB)
- Melting Point: 57 °C Source: Human Metabolome Database (HMDB)
- Odor: ODORLESS Source: Hazardous Substances Data Bank (HSDB)
- Physical Description: Solid Source: Human Metabolome Database (HMDB)
- Refractive Index: INDEX OF REFRACTION: 1.625 Source: Hazardous Substances Data Bank (HSDB)
- Solubility: 500 mg/L (at 15 °C) Source: DrugBank
- Solubility: In water, 500 mg/L at 15 °C Source: Hazardous Substances Data Bank (HSDB)
- Solubility: 1 g dissolves in: 1900 mL water, 760 mL boiling water Source: Hazardous Substances Data Bank (HSDB)
- Solubility: 1 g dissolves in: 80 mL benzene (18 mL at 50 °C), 1.2 mL chloroform, 250 mL dry ether, 20 mL glycerol, 0.8 mL alcohol, 1900 mL of 10% ammonia water; almost insoluble in petroleum ether Source: Hazardous Substances Data Bank (HSDB)
- Solubility: Soluble in ether, chloroform, carbon disulfide, glycerol, alkalies, and acids (with formation of salts) Source: Hazardous Substances Data Bank (HSDB)
- Solubility: Sol in pyrimidine Source: Hazardous Substances Data Bank (HSDB)
- Solubility: 3.34e-01 g/L Source: Human Metabolome Database (HMDB)
- pH: pH of saturated aqueous solution = 8.8 Source: Hazardous Substances Data Bank (HSDB)
- Carcinogen Classification: No indication of carcinogenicity to humans (not listed by IARC). Source: Toxin and Toxin Target Database (T3DB)
- Exposure Routes: Oral Source: Toxin and Toxin Target Database (T3DB)
- Signal: Danger Source: European Chemicals Agency (ECHA)
- GHS Hazard Statements: H302 (22.9%): Harmful if swallowed [Warning Acute toxicity, oral]; H315 (28.4%): Causes skin irritation [Warning Skin corrosion/irritation]; H317 (99.5%): May cause an allergic skin reaction [Warning Sensitization, Skin]; H319 (28.4%): Causes serious eye irritation [Warning Serious eye damage/eye irritation]; H334 (83.1%): May cause allergy or asthma symptoms or breathing difficulties if inhaled [Danger Sensitization, respiratory] Source: European Chemicals Agency (ECHA)
- Precautionary Statement Codes: P233, P260, P261, P264, P264+P265, P270, P271, P272, P280, P284, P301+P317, P302+P352, P304+P340, P305+P351+P338, P321, P330, P332+P317, P333+P317, P337+P317, P342+P316, P362+P364, P403, and P501 (click each P-code to see the statement) Source: European Chemicals Agency (ECHA)
- ECHA C&L Notifications Summary: Aggregated GHS information provided per 201 reports by companies from 10 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.; Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown. For more detailed information, please visit ECHA C&L website. Source: European Chemicals Agency (ECHA)
- Signal: Warning Source: Hazardous Chemical Information System (HCIS), Safe Work Australia
- GHS Hazard Statements: H302: Harmful if swallowed [Warning Acute toxicity, oral]; H317: May cause an allergic skin reaction [Warning Sensitization, Skin] Source: Hazardous Chemical Information System (HCIS), Safe Work Australia
- Precautionary Statement Codes: P261, P264, P270, P272, P280, P301+P317, P302+P352, P321, P330, P333+P317, P362+P364, and P501 (click each P-code to see the statement) Source: Hazardous Chemical Information System (HCIS), Safe Work Australia
- Signal: Danger Source: Hazardous Substances Data Bank (HSDB)
- GHS Hazard Statements: H315: Causes skin irritation [Warning Skin corrosion/irritation]; H317: May cause an allergic skin reaction [Warning Sensitization, Skin]; H319: Causes serious eye irritation [Warning Serious eye damage/eye irritation]; H334: May cause allergy or asthma symptoms or breathing difficulties if inhaled [Danger Sensitization, respiratory] Source: Hazardous Substances Data Bank (HSDB)
- Precautionary Statement Codes: P233, P260, P261, P264, P264+P265, P271, P272, P280, P284, P302+P352, P304+P340, P305+P351+P338, P321, P332+P317, P333+P317, P337+P317, P342+P316, P362+P364, P403, and P501 (click each P-code to see the statement) Source: Hazardous Substances Data Bank (HSDB)
- Health Effects: It is usual for quinine in therapeutic doses to cause cinchonism; in rare cases, it may even cause death (usually by pulmonary edema). Quinine can worsen hemoglobinuria, myasthenia gravis and optic neuritis. It can cause paralysis if accidentally injected into a nerve, and is extremely toxic in overdose[Wikipedia] Source: Toxin and Toxin Target Database (T3DB)
- Toxicity Summary: IDENTIFICATION AND USE: Quinine is a bulky, white, amorphous powder or crystalline alkaloid, used as medication: non-narcotic analgesics; antimalarial; central muscle relaxants. It is also used as flavor in carbonated beverages. HUMAN EXPOSURE AND TOXICITY: Serious hypersensitivity reactions, including anaphylactic shock, anaphylactoid reactions, urticaria, serious skin rashes, angioedema, facial edema, bronchospasm, and pruritus, have been reported with quinine. In addition, thrombocytopenia, hemolytic uremic syndrome/thrombotic thrombocytopenic purpura (HUS/TTP), immune thrombocytopenic purpura, blackwater fever, disseminated intravascular coagulation, leukopenia, neutropenia, granulomatous hepatitis, and acute interstitial nephritis have been reported and may also be due to hypersensitivity reactions to the drug. Potentially fatal cardiac arrhythmias, including torsades de pointes and ventricular fibrillation, have been reported rarely during quinine therapy. At least 1 case of fatal ventricular arrhythmia has been reported in a geriatric patient with preexisting prolonged QT interval treated with IV quinine sulfate for Plasmodium falciparum malaria. Visual impairment can range Source: Hazardous Substances Data Bank (HSDB)
- Toxicity Summary: The theorized mechanism of action for quinine and related anti-malarial drugs is that these drugs are toxic to the malaria parasite. Specifically, the drugs interfere with the parasite's ability to break down and digest hemoglobin. Consequently, the parasite starves and/or builds up toxic levels of partially degraded hemoglobin in itself. Source: Toxin and Toxin Target Database (T3DB)
- Uses: Medicine (antimalarial) as the alkaloid or as numerous salts and derivatives; flavoring in carbonated beverages Source: Hazardous Substances Data Bank (HSDB)
- Uses: Flavor in carbonated beverages. Source: Hazardous Substances Data Bank (HSDB)
- Uses: MEDICATION Source: Hazardous Substances Data Bank (HSDB)
- Uses: MEDICATION (VET) Source: Hazardous Substances Data Bank (HSDB)
- Uses: For more Uses (Complete) data for QUININE (8 total), please visit the HSDB record page. Source: Hazardous Substances Data Bank (HSDB)
- Uses: Use (kg; approx.) in Germany (2009): >5000; Use (kg) in USA (2002): 56800; Consumption (g per capita; approx.) in Germany (2009): 0.0611; Consumption (g per capita) in the USA (2002): 0.201; Calculated removal (%): 41.8 Source: NORMAN Suspect List Exchange
- Uses: For the treatment of malaria and leg cramps. Used as an antipyretic (fever-reducing), antimalarial, analgesic (painkilling), and anti-inflammatory. It is also used as a flavor component of tonic water and bitter lemon. Source: Toxin and Toxin Target Database (T3DB)
Mapped by: Existing checksum-valid CAS to unique PubChem CID match. Retrieved: 2026-08-31. Open source record
Scientific classifications and hazard annotations provide context and do not replace the market-specific regulatory decision shown above.
Additional source coverage and match status
| Source | Result | Checked |
|---|---|---|
| NIH PubChem PUG-View | Exact match | 2026-08-31 |
A recorded no-match is useful evidence that the source was checked; it is not a claim that the substance does not exist elsewhere.
Retrieved from NIH PubChem on 2026-08-31 by checksum-valid CAS matching. Chemical properties do not replace the regulatory decision on this page.
Additional authoritative substance research
These source-specific lookups can add hazard, toxicology, identity and assessment context. A link is a research route, not a claim that the source contains an exact record.
Cosmetic Ingredient Review safety assessments
Expert Panel conclusions, assessed ingredient groups, use conditions, dates and report documents
Independent expert review considered by FDA; not a government approval or binding market rule
Research this identityFDA Global Substance Registration System
UNII identifiers, preferred names, substance types, codes and public substance relationships
Identity registry only; UNII availability does not imply FDA review or approval
Research this identityILO/WHO International Chemical Safety Cards
Hazards, symptoms, first aid, storage, incompatibilities and physical properties for covered chemicals
International occupational chemical-safety reference; not cosmetic-use approval
Research this identityJapan NITE-CHRIP
Chemical identity, Japanese and foreign legal lists, GHS hazards and exposure-related information
Chemical-management evidence; cosmetic status remains governed by the applicable MHLW standard and market rules
Research this identityNIOSH Pocket Guide to Chemical Hazards
REL, PEL, IDLH, properties, exposure routes, symptoms, target organs, first aid and measurement methods for covered workplace chemicals
US occupational-health guidance and limits; not a cosmetic ingredient decision
Research this identityOECD eChemPortal
Gateway to authority-owned physical-property, fate, ecotoxicity, toxicity, exposure and GHS records
Discovery gateway; each linked authority remains responsible for its data
Research this identityUS EPA CompTox CTX APIs
DTXSID identity, experimental and predicted properties, toxicity, bioactivity, exposure and environmental data
Scientific and computational evidence; predictions must remain labelled and do not determine cosmetic legality
Research this identityContinue the compliance check
1. Confirm identity
Match the supplier specification, CAS/EC identifiers and composition to this official label name. Similar wording is not proof of chemical equivalence.
2. Review restrictions
Check every exact Annex record shown above, plus CMR, nanomaterial, SCCS and later-amendment requirements that may apply.
3. Verify the formula
Evaluate concentration, product type, purity, warnings, claims and each target market before making a compliance decision.
Official source and scope
Imported from Commission Implementing Decision (EU) 2025/1175 (dataset version EU 2025/1175). The glossary supplies common ingredient names for the ingredient list required by Article 19(1)(g); it is not an approval or safety list.
Open official Decision